NEW YORK, Sept. 26, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or "the Company"), will introduce its next generation targeted lymphodepletion technology for CAR-T therapy on a conference call and webcast today at 4:15 PM ET. Actinium's next generation targeted lymphodepletion technology is intended to offer a universal solution to certain key challenges facing the CAR-T industry. Actinium believes its approach may offer significant advantages to the success of CAR-T product candidates due to its improved safety and efficacy potential compared to current standard of care. Currently, CAR-T therapy relies on chemotherapy regimens such as Fludarabine (Flu) and Cyclophosphamide (Cy) for lymphodepletion conditioning, which is a requirement for the 2 approved CAR-T therapies and utilized by numerous CAR-T's in development.
Participation details for the conference call and webcast are as follows:
Date: Wednesday, September 26, 2018
Time: 4:15 PM ET
Webcast Registration: https://onecast.thinkpragmatic.com/ses/8JeRIX31t6pPlM3Dm85kJA~~
U.S. Participant Dial-in: (718) 865-8336
U.S./Canada Toll Free Dial-in: (855) 427-0225
Conference ID: 4831
Dr. Nirav Shah, Assistant Professor of Medicine, Division of Hematology and Oncology at Froedtert & the Medical College of Wisconsin, Sandesh Seth, Actinium's Chairman and CEO and Dr. Dale Ludwig, Actinium's Chief Scientific Officer will lead the call to discuss Actinium's lymphodepletion technology.
On today's webcast, Actinium will highlight the potential of its next generation lymphodepletion technology to address toxicities such as cytokine release syndrome and neurotoxicity both of which are black box warnings for the two approved CAR-T therapies. The Company will also outline its technology's value proposition to CAR-T developers and its clinical development strategy.
Actinium's next generation targeted lymphodepletion is intended to be administered as a single dose in an outpatient setting. Due to its potentially superior safety and efficacy balance as well as improved administration, Actinium believes its targeted lymphodepletion technology can be used to expand the CAR-T eligible patient population as well as improve outcomes.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior targeted conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells. The Company's targeted Antibody Radio-Conjugates (ARCs), combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Actinium is developing a pipeline of clinical-stage ARCs targeting CD45 and CD33 for patients with a broad range of hematologic malignancies.
Iomab-B, Actinium's lead product candidate, is currently enrolling patients in a pivotal Phase 3 trial. Iomab-B combines the anti-CD45 monoclonal antibody BC8 labeled with iodine-131 and is designed to condition the bone marrow prior to a bone marrow transplant without the need for intense chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) of age 55 or older. Actinium's pipeline also includes a potentially best-in-class CD33 program with our ARC comprised of the anti-CD33 antibody lintuzumab labeled with the alpha-particle emitter actinium-225. Its CD33 program is currently being studied in Phase 2 and Phase 1 clinical trials for patients with AML, myelodysplastic syndrome (MDS) and multiple myeloma.
Actinium is also developing its proprietary Actinium Warhead Enabling (AWE) technology platform to utilize the highly differentiated radioisotope actinium-225 with a wide range of targets. AWE is being utilized in a collaborative research partnership with Astellas Pharma, Inc.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.
Actinium Pharmaceuticals, Inc.
Vice President, Finance and Corporate Development
Rx Communications Group
Susan A. Noonan
SOURCE Actinium Pharmaceuticals, Inc.